Paris – Paul Hastings, a leading global law firm, announced today that the firm advised the biopharmaceutical Swiss company GeNeuro, along with underwriters Bryan Garnier & Co and Société Générale, on GeNeuro’s initial public offering and listing on the regulated market of Euronext in Paris.
This transaction is the first ever IPO of a Swiss company on the regulated market of Euronext in Paris and the first IPO of the year on this market.
The €33 million offering, which closed on April 18, 2016, consisted of a retail offering in France and an international private placement to institutional investors, including in the United States, and values the company at approximately €190 million.
Created in 2006, GeNeuro develops new treatments targeting potential causes of neurological disorders and autoimmune diseases such as multiple sclerosis and type-1 diabetes. Funds raised through this operation will notably enable to step up clinical developments in the United States and in new indications.
Paul Hastings advised GeNeuro as French and U.S. deal counsel, including providing assistance to underwriters Bryan Garnier & Co and Société Générale.
The Paul Hastings team was led by partner David Revcolevschi in Paris, assisted by associate Béatrice Dang on matters of French law, and corporate partner Peter Schwartz and associate Corey Blake in London on matters of U.S. law.
Bär & Karrer acted as Swiss law deal counsel to GeNeuro with a team led in Geneva by Christophe Buchwalder.
Paul Hastings is a leading global law firm with a strong presence throughout Asia, Europe, Latin America, and the United States. Through a collaborative approach, entrepreneurial spirit, and commitment to client service, the professionals of Paul Hastings deliver innovative solutions to many of the world’s top financial institutions and Fortune 500 companies.